← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS › Other psychostimulants and nootropics
piracetam and cinnarizine
N06BX53
Forms & Strengths
- Oral tablets: 200 mg piracetam + 25 mg cinnarizine
- Oral tablets: 400 mg piracetam + 50 mg cinnarizine
- Oral solution: 100 mg piracetam + 12.5 mg cinnarizine per mL
Adult Dosing
- 2–3 tablets daily (total 400–1200 mg piracetam + 50–75 mg cinnarizine) divided BID or TID
- Maximum daily piracetam 2400 mg; cinnarizine not to exceed 75 mg
- Adjust for renal impairment: reduce piracetam dose by 50 % if CrCl <30 mL/min
Pediatric Dosing
- Piracetam monotherapy 20–30 mg/kg/day in 2–3 divided doses (cinnarizine not recommended in <12 y)
- Combination not advised for children; if used, limit to piracetam component only
Indications
- Age‑related cognitive decline and mild memory impairment
- Peripheral vestibular disorders (vertigo, dysbalance) with associated cognitive symptoms
- Post‑concussive syndrome with attention deficits
Mechanism of Action
- Piracetam: enhances neuronal membrane fluidity, modulates AMPA receptors, improves neuroplasticity and cerebral metabolism
- Cinnarizine: selective L‑type calcium‑channel blockade, H1‑histamine antagonism, reduces vestibular hair‑cell excitability and improves microcirculation
Contraindications
- Known hypersensitivity to piracetam or cinnarizine
- Severe renal failure (piracetam) or hepatic failure (cinnarizine)
- Parkinsonian syndrome or extrapyramidal disorders (cinnarizine may aggravate)
- Children <12 y (cinnarizine component)
- Pregnancy and lactation only if benefits outweigh risks
Adverse Reactions
- Piracetam: insomnia, agitation, anxiety, headache, nausea
- Cinnarizine: drowsiness, somnolence, GI upset, weight gain, photosensitivity, rare extrapyramidal symptoms (parkinsonism, tremor)
- Combined: additive CNS depression, dizziness
Drug Interactions
- Additive CNS depression with alcohol, benzodiazepines, opioids, antihistamines
- Cinnarizine may increase effects of other calcium‑channel blockers (hypotension, bradycardia)
- Avoid concurrent dopamine antagonists (antipsychotics, metoclopramide) – higher risk of parkinsonism
- Piracetam may potentiate anticoagulant/antiplatelet activity (monitor INR)
- Cinnarizine may reduce efficacy of antihypertensives (via vasodilatory effect)
Curated Content: Needs Vetting Before Put to Clinical Use